AR029407A1 - Procedimientos para preparar derivados de la imidazolidinona antagonistas de alfa v integrina e intermediarios - Google Patents

Procedimientos para preparar derivados de la imidazolidinona antagonistas de alfa v integrina e intermediarios

Info

Publication number
AR029407A1
AR029407A1 ARP000105852A ARP000105852A AR029407A1 AR 029407 A1 AR029407 A1 AR 029407A1 AR P000105852 A ARP000105852 A AR P000105852A AR P000105852 A ARP000105852 A AR P000105852A AR 029407 A1 AR029407 A1 AR 029407A1
Authority
AR
Argentina
Prior art keywords
antagonists
imidazolidinone
integrine
alfa
intermediary
Prior art date
Application number
ARP000105852A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR029407A1 publication Critical patent/AR029407A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se provee un procedimiento para la preparacion de antagonistas de imidazolidinona alfavbeta3/alfavbeta5 integrina de formula (1) que comprende: (a) reducir el doble enlace de imidazolil-2-ona en un compuesto de formula estructural (2); y (b) disociar el grupo protector R3 en un compuesto que tiene la formula estructural (3) en donde Ar, R1 y R3 tienen el significado dado en la memoria descriptiva y los intermediarios utiles obtenidos a partir de los mismos. Estos compuestos son antagonistas de los receptores de alfavbeta3/alfavbeta5 integrina, y por lo tanto son utiles para inhibir la resorcion osea y para tratar y prevenir la osteoporosis. También se describe ácido 3-{2-oxo-3-[3(5,6,7,8-tetrahidro-[1,8]naftiridin-2-il)-propil]imidazolidin-1-il}-3(S)-(6-metoxi-piridin-3-il)-propionico en forma de un hemihidrato.
ARP000105852A 1999-11-08 2000-11-07 Procedimientos para preparar derivados de la imidazolidinona antagonistas de alfa v integrina e intermediarios AR029407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16397999P 1999-11-08 1999-11-08

Publications (1)

Publication Number Publication Date
AR029407A1 true AR029407A1 (es) 2003-06-25

Family

ID=22592461

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105852A AR029407A1 (es) 1999-11-08 2000-11-07 Procedimientos para preparar derivados de la imidazolidinona antagonistas de alfa v integrina e intermediarios

Country Status (20)

Country Link
EP (1) EP1230240B1 (es)
JP (1) JP2003513974A (es)
KR (1) KR20020048427A (es)
CN (1) CN1414966A (es)
AR (1) AR029407A1 (es)
AT (1) ATE245645T1 (es)
AU (1) AU777919B2 (es)
BR (1) BR0015384A (es)
CA (1) CA2389999A1 (es)
CZ (1) CZ20021508A3 (es)
DE (1) DE60004087T2 (es)
EA (1) EA200200548A1 (es)
ES (1) ES2202191T3 (es)
HU (1) HUP0203246A3 (es)
IL (1) IL149313A0 (es)
MX (1) MXPA02004547A (es)
PL (1) PL355011A1 (es)
SK (1) SK8012002A3 (es)
WO (1) WO2001034602A2 (es)
YU (1) YU32502A (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916810B2 (en) * 2000-09-13 2005-07-12 Merck & Co., Inc. αν integrin receptor antagonists
CA2421652A1 (en) 2000-09-14 2002-03-21 Merck And Co., Inc. Alpha v integrin receptor antagonists
US6706885B2 (en) 2001-06-06 2004-03-16 Merck & Co., Inc. Process for preparing integrin antagonist intermediates
US6509347B2 (en) 2001-06-11 2003-01-21 Merck & Co., Inc. Crystalline forms of an integrin receptor antagonist
US6646130B2 (en) 2001-07-19 2003-11-11 Merck & Co., Inc. Process to chiral integrin antagonist beta-amino acid intermediate
TW200304439A (en) * 2002-01-29 2003-10-01 Merck & Co Inc Process for preparing integrin antagonist intermediate
EP1551401A4 (en) * 2002-09-20 2006-03-22 Merck & Co Inc MANNITOL FORMULATION FOR AN INTEGRIN RECEPTOR ANTAGONIST
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
CN104053659B (zh) 2012-01-13 2016-11-09 诺华股份有限公司 用于治疗肺动脉高压(pah)及相关病症的作为ip 受体激动剂的稠合的吡咯类
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
JP6215335B2 (ja) 2013-09-24 2017-10-18 富士フイルム株式会社 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
ES2756748T3 (es) * 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
WO2017189828A1 (en) * 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
LT3538528T (lt) * 2016-11-08 2021-03-10 Bristol-Myers Squibb Company Pirolo amidai, kaip alfa v integrino inhibitoriai

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1040111E (pt) * 1997-12-17 2005-10-31 Merck & Co Inc Antagonistas do receptor da integrina

Also Published As

Publication number Publication date
ES2202191T3 (es) 2004-04-01
CN1414966A (zh) 2003-04-30
KR20020048427A (ko) 2002-06-22
DE60004087T2 (de) 2004-04-15
YU32502A (sh) 2004-12-31
JP2003513974A (ja) 2003-04-15
IL149313A0 (en) 2002-11-10
WO2001034602A3 (en) 2002-01-17
CA2389999A1 (en) 2001-05-17
HUP0203246A2 (hu) 2003-01-28
AU1461401A (en) 2001-06-06
PL355011A1 (en) 2004-03-22
HUP0203246A3 (en) 2003-12-29
EP1230240B1 (en) 2003-07-23
SK8012002A3 (en) 2002-10-08
ATE245645T1 (de) 2003-08-15
WO2001034602A2 (en) 2001-05-17
EP1230240A2 (en) 2002-08-14
CZ20021508A3 (cs) 2002-10-16
BR0015384A (pt) 2002-10-08
MXPA02004547A (es) 2002-09-02
EA200200548A1 (ru) 2002-10-31
AU777919B2 (en) 2004-11-04
DE60004087D1 (de) 2003-08-28

Similar Documents

Publication Publication Date Title
AR029407A1 (es) Procedimientos para preparar derivados de la imidazolidinona antagonistas de alfa v integrina e intermediarios
DK1120388T3 (da) Anvendelse af pyrazolderivater som nitrifikationsinhibitor
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
GEP20033114B (en) Biphenyl Sulfonamides as Dual Angiotensin Endothelin Receptor Antagonists, Method for Their Production and Pharmaceutical Compositions Containing the Same
BG105457A (en) Method for the preparation of citalopram
EA200300391A1 (ru) Имидазольные соединения, арил- или гетероарилконденсированные, в качестве противовоспалительных и анальгетических средств
BR0013179A (pt) Compostos de oxoazaeterociclila substituìda
DE69613985D1 (de) Meta-guanidine, harnstoff, thioharnstoff oder azacyklische aminobenzoesäure-derivate als integrin antagonisten
CA2400185A1 (en) Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
AR009070A1 (es) Compuestos derivados de amidinas heterociclicas de cinco miembros, su uso y compuestos intermediarios utiles para la produccion de los mismos.
BG104740A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
PE20001563A1 (es) Antagonistas del receptor de vitronectina
ATE225774T1 (de) Imidazolidinonderivate als korrosionsinhibitoren
PT942911E (pt) Compostos alfa 1 adrenergicos de benzopiranopirrolo e benzopiranopiridina
CO4950614A1 (es) Antagonistas de taquiquinina
BR9910074A (pt) Processo para fabricação de uréias 1,3-di-substituìdas-4-oxocìclicas
BR0003880A (pt) Agonistas e antagonistas de somatostatina que atuam no receptor de subtipo 2 sst
BR0207853A (pt) Produtos de condensação de ácidos hidroxicarboxìlicos e glicóis ou glicerol, úteis como doadores de ácido
CO5080739A1 (es) Compuestos antibacterianos de cefalosporinas de 7-acilamino- 3-(amino-guanidina ciclica) metileno utiles como productos farmaceuticos y procesos para su produccion
NZ520805A (en) Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same
RU97118593A (ru) ПРОИЗВОДНЫЕ 1-[ω-(3,4-ДИГИДРО-2-НАФТАЛИНИЛ)АЛКИЛ] ЦИКЛИЧЕСКОГО АМИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
EP1156047A4 (en) 6-SUBSTITUTED-7-HETEROQUINOXALINE CARBONIC ACID DERIVATIVES AND ADDITIONAL SALTS AND A METHOD FOR PRODUCING BOTH
IL155183A0 (en) Pharmaceutical compositions containing oxapenem-3-carboxylic acids
GEP20022785B (en) Processes for Preparation of Trovafloxacin Acid Salts
GEP19981168B (en) Benzimidazole derivatives and pharmaceutically acceptable salts thereof, intermediate compounds, method of their reception, stable crystals, a composition for inhibition of angiotensin ii

Legal Events

Date Code Title Description
FB Suspension of granting procedure